AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer

Journal of Physiology

Volumn 574, Issue 1, 2006, Pages 63-71

  Motoshima, Hiroyuki ^a   Goldstein, Barry J ^b   Igata, Motoyuki ^a   Araki, Eiichi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ADIPONECTIN; CHOLESTEROL; FATTY ACID; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE LKB1; PROTEIN P21; PROTEIN P53; TUBERIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CELL CYCLE; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; FATTY ACID SYNTHESIS; GENE TARGETING; HUMAN; HYPERCHOLESTEROLEMIA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL; UPREGULATION; ARTICLE; CANCER CELL; CANCER CONTROL; CARDIOVASCULAR DISEASE; CELL CYCLE REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; EUKARYOTIC CELL; GENETIC DISORDER; LKB1 GENE; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; ATHEROSCLEROSIS; CARDIOTONIC AGENTS; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 33745213627     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2006.108324     Document Type: Review

References (79)

1. Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y et al. (2002). Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105, 2893-2898.
2. Bode AM & Dong Z (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4, 793-805.
3. Bolster DR, Crozier SJ, Kimball SR & Jefferson LS (2002). AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through downregulated mTOR signaling. J Biol Chem 277, 23977-23980.
4. Boudeau J, Sapkota G & Alessi DR (2003). LKB1, a protein kinase regulating cell proliferation and polarity. FEBS Lett 546, 159-165.
5. Bowker SL, Majumdar SR, Veugelers P & Johnson JA (2006). Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254-258.
6. Brakenhielm E, Veitonmaki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T & Cao Y (2004). Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 101, 2476-2481.
7. Cantley LC (2002). The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
8. Carrera AC (2004). TOR signaling in mammals. J Cell Sci 117, 4615-4616.
9. Cheng SW, Fryer LG, Carling D & Shepherd PR (2004). Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J Biol Chem 279, 15719-15722.
10. Conlon I & Raff M (1999). Size control in animal development. Cell 96, 235-244.
11. Corton JM, Gillespie JG & Hardie DG (1994). Role of the AMP-activated protein kinase in the cellular stress response. Curr Biol 4, 315-324.
12. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS & La Vecchia C (2004). Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 89, 1160-1163.
13. Elrod JW & Lefer DJ (2005). The effects of statins on endothelium, inflammation and cardioprotection. Drug News Perspect 18, 229-236.
14. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR & Morris AD (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305.
15. Fingar DC & Blenis J (2004). Target of rapamycin (TOR): An integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23, 3151-3171.
16. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C & Blenis J (2004). mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24, 200-216.
17. Fingar DC, Salama S, Tsou C, Harlow E & Blenis J (2002). Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16, 1472-1487.
18. Forcet C, Etienne-Manneville S, Gaude H, Fournier L, Debilly S, Salmi M, Baas A, Olschwang S, Clevers H & Billaud M (2005). Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. Hum Mol Genet 14, 1283-1292.
19. Foretz M, Carling D, Guichard C, Ferre P & Foufelle F (1998). AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem 273, 14767-14771.
20. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H et al. (2003). Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11, 1457-1466.
21. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M & Offerhaus JA (2000). Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119, 1447-1453.
22. Goldstein BJ & Scalia R (2004). Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 89, 2563-2568.
23. Grana X & Reddy EP (1995). Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11, 211-219.
24. Hardie DG (2003). Minireview: The AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144, 5179-5183.
25. Hardie DG (2004). The AMP-activated protein kinase pathway - new players upstream and downstream. J Cell Sci 117, 5479-5487.
26. Hardie DG (2005). New roles for the LKB1 →AMPK pathway. Curr Opin Cell Biol 17, 167-173.
27. Hardie DG & Carling D (1997). The AMP-activated protein kinase - fuel gauge of the mammalian cell? Eur J Biochem 246, 259-273.
28. Hardie DG, Carling D & Carlson M (1998). The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell? Annu Rev Biochem 67, 821-855.
29. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP, Alessi DR & Hardie DG (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2, 28.
30. Henin N, Vincent MF, Gruber HE & Van den Berghe G (1995). Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 9, 541-546.
31. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L et al. (2002). Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12, 1419-1423.
32. Hunter T & Pines J (1994). Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79, 573-582.
33. Igata M, Motoshima H, Tsuruzoe K, Kojima K, Matsumura T, Kondo T et al. (2005). Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression. Circ Res 97, 837-844.
34. Imamura K, Ogura T, Kishimoto A, Kaminishi M & Esumi H (2001). Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287, 562-567.
35. Inoki K, Li Y, Zhu T, Wu J & Guan KL (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4, 648-657.
36. Inoki K, Zhu T & Guan KL (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590.
37. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K & Nagawa H (2005). Plasma adiponectin and gastric cancer. Clin Cancer Res 11, 466-472.
38. Jimenez AI, Fernandez P, Dominguez O, Dopazo A & Sanchez-Cespedes M (2003). Growth and molecular profile of lung cancer cells expressing ectopic LKB1: Down-regulation of the phosphatidylinositol 3′-phosphate kinase/PTEN pathway. Cancer Res 63, 1382-1388.
39. Jones RG, Plas DR, Kubek S, Buzzal M, Mu J, Xu Y, Birnbaum MJ & Thompson CB (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18, 283-293.
40. Kang JH, Lee YY, Yu BY, Yang BS, Cho KH, Yoon do K & Roh YK (2005). Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res 28, 1263-1269.
41. Karuman P, Gozani O, Odze RD, Zhou XC, Zhu H, Shaw R et al. (2001). The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 7, 1307-1319.
42. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M et al. (2003). AMP-activated protein kinase, super metabolic regulator. Biochem Soc Trans 31, 162-168.
43. Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, Hara K et al. (2003). A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 8, 65-79.
44. Krause U, Bertrand L & Hue L (2002). Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem 269, 3751-3759.
45. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL & Townsend CA (2000). Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc Natl Acad Sci U S A 97, 3450-3454.
46. Kyriakis JM (2003). At the crossroads: AMP-activated kinase and the LKB1 tumor suppressor link cell proliferation to metabolic regulation. J Biol 2, 26.
47. Leclerc I, Kahn A & Doiron B (1998). The 5′-AMP-activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex. FEBS Lett 431, 180-184.
48. Lukas J, Bartkova J & Bartek J (1996). Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16, 6917-6925.
49. Luo Z, Saha AK, Xiang X & Ruderman NB (2005). AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26, 69-76.
50. Ma L, Chen Z, Erdjument-Bromage H, Tempst P & Pandolfi PP (2005). Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193.
51. Manning BD, Tee AR, Logsdon MN, Blenis J & Cantley LC (2002). Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10, 151-162.
52. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM et al. (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89, 1102-1107.
53. Mehenni H, Gehrig C, Nezu J, Oku A, Shimane M, Rossier C et al. (1998). Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity. Am J Hum Genet 63, 1641-1650.
54. Menendez JA & Lupu R (2004). Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: From anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp 52, 414-426.
55. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D & Kahn BB (2002). Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343.
56. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y & Noguchi S (2003). Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9, 5699-5704.
57. Motoshima H, Wu X, Mahadev K & Goldstein BJ (2004). Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun 315, 264-271.
58. Nagata D, Takeda R, Sata M, Satonaka H, Suzuki E, Nagano T & Hirata Y (2004). AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation. Circulation 110, 444-451.
59. Neufeld TP & Edgar BA (1998). Connections between growth and the cell cycle. Curr Opin Cell Biol 10, 784-790.
60. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T & Walsh K (2004). Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 279, 1304-1309.
61. Rattan R, Giri S, Singh AK & Singh I (2005). 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280, 39582-39593.
62. Schmelzle T & Hall MN (2000). TOR, a central controller of cell growth. Cell 103, 253-262.
63. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA & Cantley LC (2004a). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99.
64. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA & Cantley LC (2004b). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101, 3329-3335.
65. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M & Cantley LC (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646.
66. Sherr CJ (1996). Cancer cell cycles. Science 274, 1672-1677.
67. Shieh SY, Ikeda M, Taya Y & Prives C (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91, 325-334.
68. Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W & Verhoeven G (2004). Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92, 273-279.
69. Tiainen M, Vaahtomeri K, Ylikorkala A & Makela TP (2002). Growth arrest by the LKB1 tumor suppressor: Induction of p21 (WAF1/CIP1). Hum Mol Genet 11, 1497-1504.
70. 1 cell cycle arrest. Proc Natl Acad Sci U S A 96, 9248-9251.
71. van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, van den Ouweland A et al. (1998). Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7, 1053-1057.
72. Weinberg RA (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
73. Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, Foufelle F & Carling D (2000). Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 20, 6704-6711.
74. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R & Goldstein BJ (2003). Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52, 1355-1363.
75. Xiang X, Saha AK, Wen R, Ruderman NB & Luo Z (2004). AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321, 161-167.
76. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. (2002). Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8, 1288-1295.
77. Ylikorkala A, Avizienyte E, Tomlinson IP, Tiainen M, Roth S, Loukola A et al. (1999). Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet 8, 45-51.
78. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N et al. (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96, 1723-1732.
79. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J et al. (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108, 1167-1174.